OriGene teamed up with Cell Press and created the CRISPR special edition book, a collection of CRISPR landmark articles and reviews in the recent year. You will find this beautiful book handy and informative.
OriGene was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. For the past 20 years, we strived to become better and to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research.
OriGene could not have accomplished all this without the support of its customers. We also owe our growth and innovation to the success of our customers who continue their trust in our products. We would like to take this opportunity to say
for your continued support of OriGene Technologies.
To serve the European customers even better, OriGene has acquired Acris Antibodies to become the European Headquarter of OriGene. Acris Antibodies provides customer/technical service as well as the option to order any OriGene product locally in Europe.
Learn more about the special activities going on in the next weeks
and about OriGene´s milestones:
ALK UltraMAB® Antibody (OTI1A4) Outperform D5F3 Antibody, Successfully Demonstrating Higher Sensitivity in NSCLC Immunohistochemistry Diagnostics
Recent Studies Validate High performance and Accurate Results for UltraMAB®OTI1A4 as an Effective Screening Tool for ALK Translocation in Non-Small Cell Lung Cancer patients.
Rockville, MD – April 14, 2016. A pair of recently published studies shed light on the highly interesting area on detection of ALK expression among NSCLC patients by IHC. One study was conducted by NordiQC (Aalborg, Denmark), the other by a group of Germany scientists and was published in the Journal of Thoracic Oncology. Both studies compared the performance of OTI1A4 antibody from OriGene (Rockville, MD) and the D5F3 antibody from Ventana (Tucson, AZ) in a large set of lung cancer specimens with known ALK status identified by FISH assay.weiterlesen...
OriGene & Dako Establish Multi-year Antibody Development Collaboration and Announce Commercial License Grant for “Ultra-Specific” Monoclonal Antibody for ALK Detection
Rockville, MD. February 4th, 2016 – OriGene Technologies, Inc., announced today that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB™ technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene’s mouse antiALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.
The OTI1A4 clone licensed by Dako was developed from OriGene’s proprietary UltraMAB antibody development platform and verified to an unprecedented “mono-specificity” level, ensuring superior performance in tissue evaluations and in antibody dependent applications such as immunohistochemistry (IHC).weiterlesen...
OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays
OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.weiterlesen...